Jazz Pharmaceuticals plc (JAZZ)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-03) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-K/A | FY-2025 | |||
| 10-KLatest | FY-2025 | 8-K (2026-02-24) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-05) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-05) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-02-25) · 99.1 | 8-K (2025-01-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-07-31) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-01) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | 8-K (2024-02-28) | 8-K (2024-01-08) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 | ||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Condensed Consolidated Statements of Income | — |
|
| Condensed Consolidated Statements of Loss | — |
|
| Consolidated Statements of Income (loss) | ||
| Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Comprehensive Income | ||
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statements of Comprehensive Income (loss) (P) | ||
| Consolidated Statements of Comprehensive Income (P) | ||
| Consolidated Statements of Shareholders Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Shareholders Equity (P) | — |
|
| Notes | ||
| Accrued Liabilities | — |
|
| Asset Acquisition | — |
|
| Asset Acquisition and License Agreements | — |
|
| Cash and Available-for-sale Securities | ||
| Certain Balance Sheet Items | — |
|
| Collaboration and License Agreement, Asset Purchase Agreement and Disposition | — |
|
| Collaborations and Disposition | — |
|
| Collaborations, Disposition and Business Combination | — |
|
| Commitments and Contingencies | ||
| Comprehensive Income (loss) | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Derivative Instruments and Hedging Activities | ||
| Disposition | — |
|
| Employee Benefit Plans | — |
|
| Fair Value Measurement | ||
| Goodwill and Intangible Assets | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Inventories | ||
| Leases | — |
|
| License Agreement and Asset Acquisition | — |
|
| Net Income (loss) Per Ordinary Share | ||
| Net Income Per Ordinary Share | — |
|
| Net Loss Per Ordinary Share | — |
|
| Organization and Description of Business | — |
|
| Other Current Assets | — |
|
| Pay Vs Performance Disclosure | ||
| Property, Plant and Equipment | — |
|
| Revenues | ||
| Schedule Ii Valuation and Qualifying Accounts | — |
|
| Segment and Other Information | — |
|
| Share-based Compensation | ||
| Shareholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| The Company and Summary of Significant Accounting Policies | — |
|